Health Care Providers
Developing Tools That Enable Better Patient Care
At Atossa Genetics, we know that healthcare providers are committed to providing their patients with the best care and outcomes possible. Our goal is to innovate diagnostic tools and assays that better enable healthcare providers to honor that commitment in the area of breast health. Through cutting edge research, new product introductions, and the development of educational resources for healthcare providers and patients, we are making important contributions to reducing the incidence of breast cancer and improving the quality of life for women living with the disease. Over the past several decades, health care providers have used the Pap smear to drastically reduce the incidence and mortality associated with cervical cancer. We believe that our current products and product pipeline will enable transformation in the prevention and treatment of breast cancer.
Our MASCT System in combination with the ForeCYTE Breast Health Test enable the non-invasive detection of malignant or pre-malignant breast cells and determination of lifetime breast cancer risk in healthy women as young as 18 years of age. These products give healthcare providers important new options for assessing, maintaining, and protecting patients’ breast health. The ArgusCYTE Breast Health Test provides an early warning of the presence of circulating breast cancer tumor cells (CTCs) in breast cancer patients. These cells can be detected before metastatic disease is clinically apparent, enabling earlier intervention. Information gained through the ArgusCYTE Breast Health Test can be used to guide treatment decisions in women with breast cancer and to monitor recurrence in women who have been treated successfully. The ArgusCYTE Breast Health Test is a powerful tool that helps healthcare providers to optimize the care and outcomes of their breast cancer patients.
Atossa Genetics’ research and development efforts is focused on developing additional molecular diagnostic markers that can be used to protect breast health and improve treatment for women with breast disease. Our research platform is built on a broad patent estate that is specifically focused on biomarkers that are present in nipple aspirate fluid (NAF), and we are working to elucidate specific NAF biomarker patterns
that can identify all stages of breast cancer. We intend to develop additional products that will give healthcare providers unprecedented insight into the status of their patients’ breast health at younger ages and at earlier disease stages. We believe that such products will be essential to reducing the incidence, morbidity, and mortality associated with breast cancer.
Here you will find the NAF library, Topics of Interest, and our Certifications to keep you up-to-date on the use of Nipple Aspirate Fluid (NAF) collection as an adjunct to mammography in identifying high risk women.
Topics of Interest
Breast Anatomy and Nipple Aspirate Fluid (NAF) Collection
The female breast has two main components; glandular tissue (lobes and ducts) and connective tissue. The breast is divided into 15 to 20 lobes that radiate outwards from the nipple and contain clusters of milk-producing glands. The lobes are… read more
MASCT System Clinical Testing
A clinical trial of the MASCT System was performed at the State University of New York, Stony Brook, NY to test the efficiency of NAF collection in normal volunteer women. Thirty-one healthy, non-pregnant, pre-menopausal female subjects… read more
The Role of NAF Cytology in the Identification of Atypical Ductal Hyperplasia
Atypical ductal hyperplasia (ADH) is a condition in which the cells lining the breast duct grow excessively and abnormally. Without other risk factors, it produces a five-fold increased risk of breast cancer. With a family history… read more
Preventing Breast Cancer with Medical Treatment
Drug therapy clinical trials for preventing breast cancer in high risk women are called chemoprevention trials. In a five year chemoprevention study of 19,700 women with ADH or other factors that made them at a high risk for invasive… read more
Diets Can improve NAF Findings
Changes in diet and/or the use of dietary supplements can have an impact on breast cancer occurrence and the effect can be measured by changes in NAF cytology or the presence of biomarkers in NAF. A study of the affect of dietary… read more
The Role of NAF Cytology and Molecular Diagnostic Biomarkers in Screening for Breast Cancer
The sensitivity of a test for detecting an abnormality is an important measure in screening populations for the presence of occult disease. With mammography as the well accepted Gold Standard for breast cancer screening, a comparison… read more
NAF Testing in Women with Prior Breast Cancer
Women who have had breast cancer are at a higher risk for recurrence of cancer or for a new malignancy. In 2008, there were 2.5 MM breast cancer survivors in the US. Atossa believes these women would be candidates for regular… read more
NAF Testing and Risk Assessment
The Breast Cancer Risk Assessment Tool (based on the Gail model) has been established by the National Cancer Institute (NCI) and the National Surgical Adjuvant Breast and Bowel Project (NSABP) to identify women with an increased… read more